Glycopharmacological Targets of Nicotine (GCNT4) in Humans (G51301)

Target Name: GCNT4

NCBI ID: G51301

GCNT4

Other Name(s): GCNT4_HUMAN | Glucosaminyl (N-acetyl) transferase 4, core 2 (beta-1,6-N-acetylglucosaminyltransferase) | C2GnT3 | glucosaminyl (N-acetyl) transferase 4 | Glucosaminyl (N-acetyl) transferase 4, core 2 | C2GNT3 | core2-GlcNAc-transferase 3 | Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 4 | glucosaminyl (N-acetyl) transferase 4, core 2 (beta-1,6-N-acetylglucosaminyltransferase) | Core 2-branching enzyme 3 | long intergenic non-protein coding RNA 1336 | OTTHUMP00000161946 | Core2-GlcNAc-transferase 3 | core 2-branching enzyme 3 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 4 | Core 2 beta-1,6-N-acetylglucosaminyltransferase 3 | core 2 beta-1,6-N-acetylglucosaminyltransferase 3 | LINC01336

Glycopharmacological Targets of Nicotine (GCNT4) in Humans

Nicotine, a highly addictive and toxic substance, has been shown to have various therapeutic effects on the human body. It has been linked to the development and progression of various diseases, including cancer, cardiovascular diseases, and neurological disorders. Despite its potential benefits, nicotine remains a major health concern due to its addictive nature and the risk it poses to public health.

One of the potential solutions to this problem is the use of Glycopharmacological Targets of Nicotine (GCNT4) as drug targets or biomarkers. These targets can be used to develop new treatments for nicotine-related disorders and to identify biomarkers that can predict the effectiveness of different treatments.

GCNT4 is a gene that has been shown to be involved in the nicotine response in the human body. It is a transmembrane protein that is expressed in various tissues and organs, including the brain, heart, and liver. Studies have shown that GCT4 is involved in the nicotine-induced increase in blood pressure, heart rate, and heart rate variability.

GCT4 has also been shown to play a role in the regulation of the blood flow to the brain, which is critical for the delivery of oxygen and nutrients to the brain. This is important for maintaining the health and function of the brain, and is a potential target for nicotine-related disorders.

In addition to its role in the nicotine response, GCT4 has also been shown to be involved in the regulation of other physiological processes that are important for human health. For example, it has been shown to be involved in the regulation of blood pressure, blood sugar levels, and the production of insulin.

GCT4 is also expressed in various tissues and organs that are affected by nicotine-related disorders. For example, it has been shown to be involved in the development of cancer in the lungs, and in the development of neurodegenerative disorders such as Alzheimer's disease.

Despite the potential benefits of using GCT4 as a drug target or biomarker, there are also concerns about its potential drawbacks. For example, some studies have suggested that GCT4 may be involved in the development of cancer, and that its expression may be associated with the severity of cancer-related symptoms.

Additionally, the use of GCT4 as a drug target or biomarker may also raise ethical concerns. For example, the use of GCT4 as a drug target may be seen as a form of \" genetic engineering,\" which may be perceived as a form of \"designer\" medicine.

Overall, GCT4 is a promising target for the development of new treatments for nicotine-related disorders. Further research is needed to fully understand its role in the nicotine response and to develop safe and effective treatments.

Protein Name: Glucosaminyl (N-acetyl) Transferase 4

Functions: Glycosyltransferase that mediates core 2 O-glycan branching, an important step in mucin-type biosynthesis. Does not have core 4 O-glycan or I-branching enzyme activity

The "GCNT4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GCNT4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets